PDUFA date set for idelalisib in lymphoma

Share this article:

Gilead's idelalisib got the all-clear for breakthrough designation for chronic lymphocytic leukemia (CLL), but the FDA is treating the drug like any other therapy when it comes to refractory indolent non-Hodgkin's lymphoma (NHL). BioCentury reports that the FDA set aside September 11 as the PDUFA date for this latter indication.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.